Assetmark Inc. raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15,777.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,305 shares of the company’s stock after purchasing an additional 63,900 shares during the period. Assetmark Inc. owned 0.07% of IDEXX Laboratories worth $9,999,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of IDXX. Koch Industries Inc. increased its position in shares of IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after purchasing an additional 1,396,113 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of IDEXX Laboratories by 486.4% during the second quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock worth $182,711,000 after purchasing an additional 938,888 shares in the last quarter. BlackRock Inc. increased its position in shares of IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock worth $1,146,142,000 after purchasing an additional 673,347 shares in the last quarter. Old Mutual Global Investors UK Ltd. acquired a new position in shares of IDEXX Laboratories during the second quarter worth $83,723,000. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of IDEXX Laboratories by 42.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock worth $211,567,000 after purchasing an additional 392,790 shares in the last quarter. 88.41% of the stock is currently owned by institutional investors and hedge funds.

IDXX has been the topic of a number of recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research report on Friday, October 6th. BidaskClub downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target on the stock in a research report on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 21st. Finally, Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $173.67.

In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $153.75, for a total value of $2,767,500.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at $163,678,098.75. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the completion of the sale, the chairman now directly owns 1,064,573 shares in the company, valued at $161,091,186.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 121,000 shares of company stock worth $18,334,330. 2.77% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Assetmark Inc. Acquires 63,900 Shares of IDEXX Laboratories, Inc. (IDXX)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/assetmark-inc-acquires-63900-shares-of-idexx-laboratories-inc-idxx/1719936.html.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded down $0.65 during midday trading on Wednesday, hitting $154.94. The company had a trading volume of 91,166 shares, compared to its average volume of 710,027. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. IDEXX Laboratories, Inc. has a 52-week low of $113.47 and a 52-week high of $173.01. The firm has a market cap of $13,553.79, a P/E ratio of 52.32, a price-to-earnings-growth ratio of 2.35 and a beta of 0.46.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million for the quarter, compared to the consensus estimate of $492.94 million. During the same period in the prior year, the firm earned $0.62 EPS. The firm’s revenue was up 9.7% on a year-over-year basis. sell-side analysts predict that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.